Immunotherapy after surgery for lung cancer with no remaining cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with stage II or III non-small cell lung cancer (but not N3).
- You had surgery to remove all visible cancer (lobectomy, sleeve, bi-lobectomy, or pneumonectomy) within the last 12 weeks.
- After surgery, no cancer cells were found in the removed tissue or lymph nodes (called a pathologic complete response).
- Before surgery, you received at least 2 cycles of chemotherapy plus an immunotherapy drug (like Keytruda or Opdivo).
- Your tumor does not have EGFR mutations or ALK gene fusions.
- You are generally healthy enough to receive immunotherapy, with no active autoimmune disease or severe side effects from prior treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of immunotherapy (durvalumab) and chemotherapy before surgery or radiation for people with stage III lung cancer that is on the edge of being removable. The goal is to shrink the tumor enough to allow surgery or more effective radiation.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests whether adding immunotherapy (durvalumab) to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. It is for people who have had their cancer completely removed and are well enough to start treatment soon after surgery.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Hear when a new Stage II Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.